Hydroxychloroquine: First Large Study Does Not Support Routine Use in COVID-19 Patients

May 12, 2020

Hydroxychloroquine: First Large Study Does Not Support Routine Use in COVID-19 Patients

Posted by Saúl Morales Rodriguéz in category: biotech/medical

A study of nearly 1,400 patients with moderate to severe COVID-19 disease at a single New York hospital found that patients who received the drug fared no better than patients who did not receive the drug.

Leave a reply

GETAS THREAT LEVEL: GUARDED
TOP DONOR: BRIAN CARTMELL
#2 DONOR: DONALD MACLEAN
#3 DONOR: JEFF BONE/TOPSIGHT FUND
#4 DONOR: PEG KAY

LF FUND: $601,282.98
BITCOIN ENDOWMENT: $8,040,811.42
A-PRIZE: $30,015.00
NANOSHIELD: $17,018.00
X-RISKS NETWORK: $3,108.00
AISHIELD: $4,114.00

LIFEBOAT NEWS: 3,049 SUBSCRIBERS
GETAS ALERTS: 439 SUBSCRIBERS
BLOG: 51,481 POSTS
BOARDS: 2,852 MEMBERS
REPORTS: 55
PROGRAMS: 25
FORUMS: 13
QUOTES: 136

FACEBOOK: 8,341 MEMBERS
LINKEDIN: 1,983 MEMBERS
TWITTER FEED: 32,811 MEMBERS
FIGHT AIDS: 3 MEMBERS
[email protected]: 15 MEMBERS
[email protected]: 44 MEMBERS
A-PRIZE: 55 MEMBERS
NANOSHIELD: 69 MEMBERS
AISHIELD: 25 MEMBERS

DONORS: 4,072
LF-500: 13 MEMBERS
PATRON: 1 MEMBER
FIRST CLASS: 1 MEMBER
EXECUTIVE: 12 MEMBERS
ECONOMY: 23 MEMBERS
A-500: 1 MEMBER

© 2002–2020 Lifeboat Foundation